相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment
Jarek Harezlak et al.
AIDS (2011)
In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells
R. Rossi et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
Clinical use of CCR5 inhibitors in HIV and beyond
Bruce L. Gilliam et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
The chemokine receptor CCR5 in the central nervous system
Silvia Sorce et al.
PROGRESS IN NEUROBIOLOGY (2011)
Downregulation of Leukocyte Migration After Treatment With CCR5 Antagonist Maraviroc
Raffaella Rossi et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
HIV-1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment
Arvid Eden et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
HIV-1 neuroimmunity in the era of antiretroviral therapy
Stephanie D. Kraft-Terry et al.
NEUROBIOLOGY OF DISEASE (2010)
Pathogenesis of HIV in the Central Nervous System
Victor Valcour et al.
Current HIV/AIDS Reports (2010)
When and how to use maraviroc in HIV-infected patients
Vincent Soriano et al.
AIDS (2009)
CCR5 antagonism in HIV infection: ways, effects, and side effects
Pierre Corbeau et al.
AIDS (2009)
Complexity in human immunodeficiency virus type 1 (HIV-1) co-receptor usage: roles of CCR3 and CCR5 in HIV-1 infection of monocyte-derived macrophages and brain microglia
Lokesh Agrawal et al.
JOURNAL OF GENERAL VIROLOGY (2009)
Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy
V. A. Cardenas et al.
JOURNAL OF NEUROVIROLOGY (2009)
Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection
Sharon S. Lieberman-Blum et al.
CLINICAL THERAPEUTICS (2008)
HIV protease inhibitors impact on apoptosis
Stacey A. Rizza et al.
MEDICINAL CHEMISTRY (2008)
Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies
Claudio M. Mastroianni et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Antiretroviral therapy inhibits matrix metal loproteinase-9 from blood mononuclear cells of HIV-infected patients
Tiziana Latronico et al.
AIDS (2007)
Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases
Nicole L. Webster et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
The paradox of matrix metalloproteinases in infectious disease
PTG Elkington et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Mechanisms of the blood-brain barrier disruption in HIV-1 infection
M Toborek et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2005)
Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis
WG Glass et al.
JOURNAL OF IMMUNOLOGY (2004)
Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia
GM Liuzzi et al.
BRAIN (2004)
Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: Links to HIV-1 dementia
R Suryadevara et al.
GLIA (2003)
Matrix metalloproteinases and tissue inhibitors of metalloproteinases - Structure, function, and biochemistry
R Visse et al.
CIRCULATION RESEARCH (2003)
Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2)
WJ Lee et al.
GLIA (2003)
分享论文
